IMMUNE PHARMACEUTICALS INC (OTCMKTS:IMNPQ) Can’t Be More Risky. Short Interest Increased

The stock of IMMUNE PHARMACEUTICALS INC (OTCMKTS:IMNPQ) registered an increase of 27.22% in short interest. IMNPQ’s total short interest was 61,700 shares in September as published by FINRA. Its up 27.22% from 48,500 shares, reported previously. With 786,800 shares average volume, it will take short sellers 0 days to cover their IMNPQ’s short positions.

The stock decreased 21.82% or $0.0012 during the last trading session, reaching $0.0043. About 12,253 shares traded. Immune Pharmaceuticals, Inc. (OTCMKTS:IMNPQ) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company has market cap of $743,375. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It currently has negative earnings. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis.

More important recent Immune Pharmaceuticals, Inc. (OTCMKTS:IMNPQ) news were published by: which released: “Immune Pharmaceuticals And Bertilimumab: A Work In Progress – Seeking Alpha” on June 22, 2018, also published article titled: “Immune Pharmaceuticals (IMNP) Presents At Noble Financial Capital Markets 14th Annual Investor Conference – Slideshow – Seeking Alpha”, published: “Immune Pharmaceuticals: Not The AML Drug You’re Looking For – Seeking Alpha” on June 02, 2016. More interesting news about Immune Pharmaceuticals, Inc. (OTCMKTS:IMNPQ) was released by: and their article: “Immune Pharmaceuticals: 5 Big Warning Signs – Seeking Alpha” with publication date: February 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.